BWX Technologies, Inc. (NYSE: BWXT)

$202.91 ▲ +1.23 (+0.61%)

As of May 22, 2026 04:00 PM

Sector: Industrials Industry: Aerospace & Defense CIK: 0001486957

Market Cap 18.60 Bn

P/E 53.82

P/S 5.51

Div. Yield 0.01

ROIC (Qtr) 0.00

Total Debt (Qtr) 2.02 Bn

Revenue Growth (1y) (Qtr) 26.08

Add ratio to table...

About

BWX Technologies, Inc. is a specialty manufacturer of nuclear components a developer of nuclear technologies and a service provider with over a century of operating history. The company focuses on the design engineering and manufacture of precision naval nuclear components nuclear reactors and nuclear fuel for the United States government. It also provides special nuclear materials processing environmental site restoration services products and services to the nuclear power industry critical medical radioisotopes and radiopharmaceuticals and other...

BWX Technologies, Inc. is a specialty manufacturer of nuclear components a developer of nuclear technologies and a service provider with over a century of operating history. The company focuses on the design engineering and manufacture of precision naval nuclear components nuclear reactors and nuclear fuel for the United States government. It also provides special nuclear materials processing environmental site restoration services products and services to the nuclear power industry critical medical radioisotopes and radiopharmaceuticals and other advanced nuclear technologies. Its legacy dates back to the early twentieth century when it began supplying parts for naval propulsion systems and has since grown into a diversified enterprise that serves defense energy and health care markets. BWX Technologies combines manufacturing engineering and service capabilities to deliver full life cycle solutions for complex nuclear projects.

Revenue is derived primarily from long term contracts with the U. S. Department of Energy and the National Nuclear Security Administration for the design production and testing of naval nuclear propulsion components reactors and fuel. The company also generates income from the sale of commercial nuclear steam generators heat exchangers pressure vessels and related equipment to nuclear power utilities in North America Europe and Asia. Additional revenue comes from the provision of medical radioisotopes radiopharmaceuticals and associated services to hospitals research institutions and pharmaceutical firms. Furthermore BWX Technologies earns fees for managing and operating government owned nuclear facilities performing environmental remediation and providing technical support for space nuclear propulsion programs. Service income also includes routine maintenance outage support and emergency response work for nuclear power plants.

The company operates through the following segments: Government Operations and Commercial Operations.

• Government Operations engineers designs and manufactures precision naval nuclear components reactors and nuclear fuel for the U. S. Department of Energy and the National Nuclear Security Administration's Naval Nuclear Propulsion Program. This segment supplies proprietary valves manifolds and fittings to global naval and commercial shipping customers. It focuses on close tolerance high quality equipment for nuclear applications and designs advanced reactors for power and propulsion uses. The business also downblends Cold War era high enriched uranium produces depleted uranium and creates advanced materials for commercial military and space projects. Additionally Government Operations manages and operates U. S. government facilities including national laboratories and weapons sites under contracts with the Department of Energy the National Nuclear Security Administration and NASA. The segment invests in research and development to improve fuel performance reduce waste and support next generation reactor concepts.

• Commercial Operations designs and manufactures commercial nuclear steam generators heat exchangers pressure vessels reactor components and auxiliary equipment such as containers for the storage of spent nuclear fuel and high level waste. The segment supplies nuclear fuel fuel handling systems reactor controls specialty tooling nuclear grade materials and precisely machined components to nuclear power plants worldwide. It provides engineering and in plant services including inspection maintenance modification and life cycle support for reactors. Commercial Operations also produces medical radioisotopes radiopharmaceuticals and medical devices and partners with life science and pharmaceutical companies on drug development projects. Its revenue depends on the demand for nuclear energy and the need for medical isotopes in diagnostic and therapeutic applications. The business maintains a global supply chain that sources raw materials from qualified vendors and performs rigorous testing to meet industry standards.

BWX Technologies holds a strong position in the nuclear industry due to its long history of supplying the U. S. government with critical nuclear components and its ability to meet stringent security and quality standards. The company faces limited competition in its Government Operations segment because of the high capital investment technical expertise and regulatory clearances required to work on classified defense projects. Primary competitors in this area include Bechtel National Amentum Fluor Northrop Grumman Huntington Ingalls Honeywell Leidos Westinghouse and AtkinsRéalis. In the Commercial Operations segment the firm competes with suppliers such as Framatome Cameco Doosan AECOM Westinghouse and AtkinsRéalis for steam generators heat exchangers and fuel handling services. Its medical isotope business contends with companies like Curium Pharma SHINE Technologies and Jubilant DraxImage. Competitive advantages stem from over a hundred years of experience a sole source status on many specialized parts a skilled workforce and proven performance on complex government contracts.

The company's largest customer is the U. S. Government which accounted for about sixty eight percent of total revenue in the most recent fiscal year. BWX Technologies also serves the Canadian government through contracts to manage and operate the Canadian National Laboratory. Nuclear power utilities in the United States Canada Europe and Asia represent a major portion of its commercial sales. Health care providers hospitals and pharmaceutical companies receive medical radioisotopes and radiopharmaceuticals from BWX Technologies. Additionally agencies such as NASA and the Department of Energy rely on the firm for space nuclear propulsion research and environmental remediation projects. The firm's diversified base reduces reliance on any single market and provides stability amid fluctuations in defense spending or energy demand.

Investment thesis

Bull case

BWXT’s record‑breaking backlog of $7.4 billion, coupled with a book‑to‑bill ratio of 2.6, signals a robust and highly secure revenue pipeline that is largely insulated from short‑term market volatility. The bulk of this backlog stems from multi‑year defense fuels and high‑purity depleted uranium contracts, which typically offer predictable cash flows and favorable risk‑adjusted returns. Management’s consistent ability to convert orders into revenue while maintaining margins in the 19‑plus percent range for government operations underscores the firm’s operational discipline and strong contractual positioning. As the defense community’s modernization agenda accelerates, these contracts are likely to extend into the 2026 and 2027 horizon, providing a stable foundation for continued top‑line growth. In a sector where funding cycles can be protracted, BWXT’s early lock‑in of high‑value work places it in a position to capture incremental margin upside as execution progresses and early‑phase cost burdens recede.
The acquisition of Kinetrix in early 2025 has delivered an immediate and tangible lift to the commercial segment, with a 122 % rise in commercial adjusted EBITDA and a margin expansion from 13.5 % to 17.0 % over the nine‑month period. Kinetrix’s expertise in offshore wind component testing, combined with its medical radioisotope business, dovetails with BWXT’s existing commercial capabilities, creating cross‑sell opportunities across the clean‑energy and nuclear markets. Early revenue from Kinetrix already represents a 10‑plus percent contribution to the commercial segment, while the integration of medical isotopes promises a recurring subscription‑like revenue stream that is less exposed to capital intensity. By harnessing Kinetrix’s proprietary design‑for‑assembly processes, BWXT can further accelerate production timelines and reduce per‑unit cost, reinforcing its high‑margin competitive moat. The synergy not only boosts short‑term earnings but also enhances BWXT’s attractiveness to investors seeking exposure to the growing low‑carbon energy transition.
BWXT’s pioneering work on the Project Pele microreactor and the Janus program places it as an early mover in the emerging Generation‑IV high‑temperature gas‑cooled reactor space, a market that is expected to grow as national security and commercial power demands converge. The successful shipment of TRISO fuel to Idaho National Laboratory (INL) for Pele’s prototype demonstrates the firm’s manufacturing readiness and compliance with the most stringent licensing regimes, thereby validating its technology platform in real‑world testing environments. The Janus program’s focus on transportable power systems for critical infrastructure positions BWXT to capture new defense and commercial contracts that value reliability and resilience, especially in scenarios where grid outages could impair traditional power supplies. Because these programs are tightly coupled with federal research and development budgets, BWXT is poised to convert early investment into commercial revenue streams as partner utilities and operators move from prototype to deployment. The strategic advantage derived from owning both fuel fabrication and system integration capabilities should insulate the company from the typical “black swan” competition that plagues newer entrants in the nuclear technology space.
The recently inaugurated Digital Center in Cambridge and the broader investment in AI‑driven automation signal BWXT’s commitment to cutting‑edge operational excellence. By integrating digital workflows, predictive maintenance, and real‑time quality control, the firm can significantly reduce labor intensity and scrap rates across its specialty fuels and component manufacturing lines. The anticipated cost savings are not merely theoretical; early telemetry from the Digital Center indicates a 5 % lift in throughput within the first 12 months, a figure that is expected to grow as the platform scales. Moreover, AI‑enabled design reviews in the Owner’s Engineer (OE) services contract for Bulgaria’s Kozloduy NPP project showcase BWXT’s ability to embed advanced analytics directly into the value chain, creating a differentiated service offering that competitors will struggle to replicate. As the firm’s operating cash flow eclipses $140 million quarterly, the residual cash can be redeployed into capex and new acquisitions with minimal risk of liquidity constraints, reinforcing its long‑term earnings prospects.
BWXT’s capital structure has evolved to become one of its strongest competitive advantages. The 2025 convertible senior notes issuance, featuring zero coupon and a favourable conversion price, will be fully repaid against a new $1.25 billion revolving credit facility, thereby reducing debt exposure while avoiding shareholder dilution. With current long‑term debt of $1.5 billion and a conservative leverage profile, the company maintains sufficient financial flexibility to fund both the $114 million projected capex in 2026 and potential opportunistic acquisitions in the specialty nuclear component space. The healthy free cash flow—already projected to exceed $285 million for the fiscal year—provides a buffer to weather short‑term market shocks or unforeseen capital requirements. Additionally, the debt covenant structure, coupled with a high credit rating, positions BWXT to negotiate favourable borrowing terms in the future, further strengthening its balance sheet resilience.

BWXT’s record‑breaking backlog of $7.4 billion, coupled with a book‑to‑bill ratio of 2.6, signals a robust and highly secure revenue pipeline that is largely insulated from short‑term market volatility. The bulk of this backlog stems from multi‑year defense fuels and high‑purity depleted uranium contracts, which typically offer predictable cash flows and favorable risk‑adjusted returns. Management’s consistent ability to convert orders into revenue while maintaining margins in the 19‑plus percent range for government operations underscores the firm’s operational discipline and strong contractual positioning. As the defense community’s modernization agenda accelerates, these contracts are likely to extend into the 2026 and 2027 horizon, providing a stable foundation for continued top‑line growth. In a sector where funding cycles can be protracted, BWXT’s early lock‑in of high‑value work places it in a position to capture incremental margin upside as execution progresses and early‑phase cost burdens recede.
The acquisition of Kinetrix in early 2025 has delivered an immediate and tangible lift to the commercial segment, with a 122 % rise in commercial adjusted EBITDA and a margin expansion from 13.5 % to 17.0 % over the nine‑month period. Kinetrix’s expertise in offshore wind component testing, combined with its medical radioisotope business, dovetails with BWXT’s existing commercial capabilities, creating cross‑sell opportunities across the clean‑energy and nuclear markets. Early revenue from Kinetrix already represents a 10‑plus percent contribution to the commercial segment, while the integration of medical isotopes promises a recurring subscription‑like revenue stream that is less exposed to capital intensity. By harnessing Kinetrix’s proprietary design‑for‑assembly processes, BWXT can further accelerate production timelines and reduce per‑unit cost, reinforcing its high‑margin competitive moat. The synergy not only boosts short‑term earnings but also enhances BWXT’s attractiveness to investors seeking exposure to the growing low‑carbon energy transition.
BWXT’s pioneering work on the Project Pele microreactor and the Janus program places it as an early mover in the emerging Generation‑IV high‑temperature gas‑cooled reactor space, a market that is expected to grow as national security and commercial power demands converge. The successful shipment of TRISO fuel to Idaho National Laboratory (INL) for Pele’s prototype demonstrates the firm’s manufacturing readiness and compliance with the most stringent licensing regimes, thereby validating its technology platform in real‑world testing environments. The Janus program’s focus on transportable power systems for critical infrastructure positions BWXT to capture new defense and commercial contracts that value reliability and resilience, especially in scenarios where grid outages could impair traditional power supplies. Because these programs are tightly coupled with federal research and development budgets, BWXT is poised to convert early investment into commercial revenue streams as partner utilities and operators move from prototype to deployment. The strategic advantage derived from owning both fuel fabrication and system integration capabilities should insulate the company from the typical “black swan” competition that plagues newer entrants in the nuclear technology space.
The recently inaugurated Digital Center in Cambridge and the broader investment in AI‑driven automation signal BWXT’s commitment to cutting‑edge operational excellence. By integrating digital workflows, predictive maintenance, and real‑time quality control, the firm can significantly reduce labor intensity and scrap rates across its specialty fuels and component manufacturing lines. The anticipated cost savings are not merely theoretical; early telemetry from the Digital Center indicates a 5 % lift in throughput within the first 12 months, a figure that is expected to grow as the platform scales. Moreover, AI‑enabled design reviews in the Owner’s Engineer (OE) services contract for Bulgaria’s Kozloduy NPP project showcase BWXT’s ability to embed advanced analytics directly into the value chain, creating a differentiated service offering that competitors will struggle to replicate. As the firm’s operating cash flow eclipses $140 million quarterly, the residual cash can be redeployed into capex and new acquisitions with minimal risk of liquidity constraints, reinforcing its long‑term earnings prospects.
BWXT’s capital structure has evolved to become one of its strongest competitive advantages. The 2025 convertible senior notes issuance, featuring zero coupon and a favourable conversion price, will be fully repaid against a new $1.25 billion revolving credit facility, thereby reducing debt exposure while avoiding shareholder dilution. With current long‑term debt of $1.5 billion and a conservative leverage profile, the company maintains sufficient financial flexibility to fund both the $114 million projected capex in 2026 and potential opportunistic acquisitions in the specialty nuclear component space. The healthy free cash flow—already projected to exceed $285 million for the fiscal year—provides a buffer to weather short‑term market shocks or unforeseen capital requirements. Additionally, the debt covenant structure, coupled with a high credit rating, positions BWXT to negotiate favourable borrowing terms in the future, further strengthening its balance sheet resilience.

Bear case

The partial government shutdown that began in early October 2025 introduces a palpable risk that BWXT’s early‑phase government contracts—particularly those in naval propulsion and technical services—could experience funding cuts or outright cancellations. Management’s evasive remarks during the earnings call about the shutdown’s duration, coupled with the fact that these contracts typically generate the lowest margins in the backlog, suggest a potential erosion of profitability if federal appropriations are delayed or reallocated. The company’s reliance on a high concentration of defense‑related work therefore exposes it to cyclical budget uncertainty that could materialize into significant revenue shortfalls. This risk is further amplified by the current uncertainty surrounding the U.S. debt ceiling, which could compel the Treasury to enact spending restraints or sequestration that would slow or halt procurement schedules. Consequently, investors should be wary of the fragility of the revenue pipeline amid a volatile policy environment that could derail government‑driven work.
Although BWXT’s backlog numbers are impressive, the company still faces substantial capacity constraints and high material procurement costs that are expected to compress margins in the short term. The nine‑month cost of goods for commercial operations rose from $13.5 million to $35.5 million in the third quarter, indicating a 22‑plus percent increase in manufacturing overheads. The firm’s own disclosures highlight the need for significant capital outlays—$48 million in capex in Q3 alone—to keep pace with demand, implying that any supply‑chain bottlenecks could force further cost escalations. These elevated cost pressures, coupled with the early‑phase nature of the backlog, create a narrow margin window that could be eroded if material price spikes or logistical disruptions occur. In such a scenario, BWXT’s historically strong profitability could be undermined, potentially leading to a decline in operating income and diminished free cash flow.
The SMR and commercial nuclear component markets are becoming increasingly crowded, with several new entrants offering competing designs and lower-cost alternatives. While BWXT has secured early contracts for SMR component manufacturing, it faces competitive pressure from companies that are actively advancing Gen‑III and Gen‑IV reactor technology platforms, potentially driving down pricing or forcing BWXT to offer discounts to secure or retain orders. The firm’s own statements about “early‑phase margin compression” in government operations highlight that similar dynamics could be at play in the SMR component space, where high fixed costs must be amortized across a limited number of orders. If BWXT’s competitors achieve higher efficiency or lower cost of production, the company could lose market share or be forced to lower prices to win or maintain bids, further compressing its profit profile. This risk of market saturation and price war is particularly acute in a niche industry where product differentiation is relatively modest and customers can easily switch suppliers.
BWXT’s dependency on defense fuels and high‑purity depleted uranium introduces commodity‑price volatility that can have a material impact on cost structures. The cost of enrichment, raw material procurement, and regulatory compliance are subject to fluctuations that can erode gross margins, especially if the price of uranium or the cost of energy used in the enrichment process rises. Management’s brief mention of “cost of enrichment and production” during the call suggests a sensitivity that is not fully quantified, leaving uncertainty about how well the firm can hedge or pass these costs onto customers. In addition, political shifts—such as changes in export controls or international agreements—could constrain BWXT’s ability to access global markets for certain high‑purity materials, limiting revenue potential. The combination of commodity risk and geopolitical factors presents a tail‑risk that could materialize if market conditions shift unfavorably, negatively affecting BWXT’s earnings.
The convertible senior notes due 2030, while providing a clean source of capital, also carry the risk of dilution if the conversion option is exercised, which could exert downward pressure on the share price. Management’s decision to include capped call transactions to mitigate potential dilution indicates a conscious attempt to protect shareholder value, yet the effectiveness of these hedges is uncertain and depends on market participation and volatility. Moreover, the notes are interest‑free, but the conversion price is set at a premium to current market value, meaning that a significant upside scenario is required before conversion is economically attractive to holders; otherwise, the firm may need to repurchase or extend the notes, affecting cash balances. These dynamics add an element of uncertainty to the capital structure that could impact both the company’s cost of capital and its free cash flow generation capacity. If dilution or increased debt servicing costs materialize, they could constrain BWXT’s ability to fund future acquisitions or capex projects, thereby affecting long‑term growth prospects.

The partial government shutdown that began in early October 2025 introduces a palpable risk that BWXT’s early‑phase government contracts—particularly those in naval propulsion and technical services—could experience funding cuts or outright cancellations. Management’s evasive remarks during the earnings call about the shutdown’s duration, coupled with the fact that these contracts typically generate the lowest margins in the backlog, suggest a potential erosion of profitability if federal appropriations are delayed or reallocated. The company’s reliance on a high concentration of defense‑related work therefore exposes it to cyclical budget uncertainty that could materialize into significant revenue shortfalls. This risk is further amplified by the current uncertainty surrounding the U.S. debt ceiling, which could compel the Treasury to enact spending restraints or sequestration that would slow or halt procurement schedules. Consequently, investors should be wary of the fragility of the revenue pipeline amid a volatile policy environment that could derail government‑driven work.
Although BWXT’s backlog numbers are impressive, the company still faces substantial capacity constraints and high material procurement costs that are expected to compress margins in the short term. The nine‑month cost of goods for commercial operations rose from $13.5 million to $35.5 million in the third quarter, indicating a 22‑plus percent increase in manufacturing overheads. The firm’s own disclosures highlight the need for significant capital outlays—$48 million in capex in Q3 alone—to keep pace with demand, implying that any supply‑chain bottlenecks could force further cost escalations. These elevated cost pressures, coupled with the early‑phase nature of the backlog, create a narrow margin window that could be eroded if material price spikes or logistical disruptions occur. In such a scenario, BWXT’s historically strong profitability could be undermined, potentially leading to a decline in operating income and diminished free cash flow.
The SMR and commercial nuclear component markets are becoming increasingly crowded, with several new entrants offering competing designs and lower-cost alternatives. While BWXT has secured early contracts for SMR component manufacturing, it faces competitive pressure from companies that are actively advancing Gen‑III and Gen‑IV reactor technology platforms, potentially driving down pricing or forcing BWXT to offer discounts to secure or retain orders. The firm’s own statements about “early‑phase margin compression” in government operations highlight that similar dynamics could be at play in the SMR component space, where high fixed costs must be amortized across a limited number of orders. If BWXT’s competitors achieve higher efficiency or lower cost of production, the company could lose market share or be forced to lower prices to win or maintain bids, further compressing its profit profile. This risk of market saturation and price war is particularly acute in a niche industry where product differentiation is relatively modest and customers can easily switch suppliers.
BWXT’s dependency on defense fuels and high‑purity depleted uranium introduces commodity‑price volatility that can have a material impact on cost structures. The cost of enrichment, raw material procurement, and regulatory compliance are subject to fluctuations that can erode gross margins, especially if the price of uranium or the cost of energy used in the enrichment process rises. Management’s brief mention of “cost of enrichment and production” during the call suggests a sensitivity that is not fully quantified, leaving uncertainty about how well the firm can hedge or pass these costs onto customers. In addition, political shifts—such as changes in export controls or international agreements—could constrain BWXT’s ability to access global markets for certain high‑purity materials, limiting revenue potential. The combination of commodity risk and geopolitical factors presents a tail‑risk that could materialize if market conditions shift unfavorably, negatively affecting BWXT’s earnings.
The convertible senior notes due 2030, while providing a clean source of capital, also carry the risk of dilution if the conversion option is exercised, which could exert downward pressure on the share price. Management’s decision to include capped call transactions to mitigate potential dilution indicates a conscious attempt to protect shareholder value, yet the effectiveness of these hedges is uncertain and depends on market participation and volatility. Moreover, the notes are interest‑free, but the conversion price is set at a premium to current market value, meaning that a significant upside scenario is required before conversion is economically attractive to holders; otherwise, the firm may need to repurchase or extend the notes, affecting cash balances. These dynamics add an element of uncertainty to the capital structure that could impact both the company’s cost of capital and its free cash flow generation capacity. If dilution or increased debt servicing costs materialize, they could constrain BWXT’s ability to fund future acquisitions or capex projects, thereby affecting long‑term growth prospects.

Segments Breakdown of Revenue (2025)

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer comparison

Companies in the Aerospace & Defense

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GE	General Electric Co	316.77 Bn	37.30	6.56	20.28 Bn
2	RTX	RTX Corp	238.61 Bn	32.72	2.64	33.20 Bn
3	BA	Boeing Co	172.59 Bn	85.22	1.87	47.21 Bn
4	LMT	Lockheed Martin Corp	122.59 Bn	25.72	1.63	20.70 Bn
5	HWM	Howmet Aerospace Inc.	102.88 Bn	59.11	11.93	4.69 Bn
6	GD	General Dynamics Corp	92.64 Bn	21.28	1.72	8.01 Bn
7	RKLB	Rocket Lab Corp	82.19 Bn	-424.25	120.95	0.00 Bn
8	NOC	Northrop Grumman Corp /De/	78.95 Bn	17.36	1.86	14.41 Bn

Research Tools

Developers

BWX Technologies, Inc. (NYSE: BWXT)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

BWX Technologies, Inc. (NYSE: BWXT)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password